{"protocolSection": {"identificationModule": {"nctId": "NCT00575588", "orgStudyIdInfo": {"id": "D1680C00001"}, "secondaryIdInfos": [{"id": "EudraCT number 2007-003998-55"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period", "officialTitle": "A 52-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone."}, "statusModule": {"statusVerifiedDate": "2012-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-12"}, "primaryCompletionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-12-14", "studyFirstSubmitQcDate": "2007-12-14", "studyFirstPostDateStruct": {"date": "2007-12-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-08-10", "resultsFirstSubmitQcDate": "2010-08-10", "resultsFirstPostDateStruct": {"date": "2010-09-06", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-03-20", "lastUpdatePostDateStruct": {"date": "2012-03-21", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin."}, "conditionsModule": {"conditions": ["Type 2 Diabetes"], "keywords": ["DPP-4 Inhibitors", "HbA1c", "incretins"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 891, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Saxagliptin", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Metformin", "Drug: Saxagliptin"]}, {"label": "Glipizide", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Metformin", "Drug: Sulphonylurea"]}], "interventions": [{"type": "DRUG", "name": "Metformin", "description": "open-label metformin", "armGroupLabels": ["Glipizide", "Saxagliptin"]}, {"type": "DRUG", "name": "Sulphonylurea", "description": "Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)", "armGroupLabels": ["Glipizide"]}, {"type": "DRUG", "name": "Saxagliptin", "description": "Saxagliptin 5 mg tablets", "armGroupLabels": ["Saxagliptin"], "otherNames": ["Onglyza"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Hemoglobin A1c (HbA1c) Change From Baseline to Week 52", "description": "Adjusted mean change from baseline in HbA1c achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 52 (Per Protocol Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated as the Week 52 value minus the baseline value.", "timeFrame": "Baseline to 52 Weeks"}], "secondaryOutcomes": [{"measure": "Proportion of Participants Reporting at Least One Episode of Any Hypoglycaemic Event Over 52 Weeks", "description": "Proportion of participants reporting at least one episode of any hypoglycaemic event for saxagliptin added on to metformin versus glipizide added on to metformin over 52 weeks (Safety Analysis Set)", "timeFrame": "From Baseline to Week 52"}, {"measure": "Body Weight Change From Baseline to Week 52", "description": "Adjusted mean change from baseline in Body Weight achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 52 (Safety Analysis Set). Body Weight is a continuous measure, the change from baseline for each participant is calculated as the Week 52 (LOCF) value minus the baseline value.", "timeFrame": "Baseline, Week 52 (Last Observation Carried Forward)"}, {"measure": "Mean Slope of the Regressions of Change From Week 24 to Week 52 in HbA1c", "description": "Mean slopes of regression of change from Week 24 to Week 52 in HbA1c for saxagliptin added on to metformin versus glipizide added on to metformin (Per Protocol Analysis Set) achieved by fitting a mixed model with subject specific slopes for the time effect (weeks on randomized treatment was utilized). This analysis gives an assessment of the durability of the HbA1c effect.", "timeFrame": "Week 24 to Week 52"}], "otherOutcomes": [{"measure": "Hemoglobin A1c (HbA1c) Change From Baseline to Week 104", "description": "Adjusted mean change from baseline in HbA1c achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 104 (Full Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated as the Week 104 value minus the baseline value.", "timeFrame": "Baseline, Week 104"}, {"measure": "Proportion of Participants Reporting at Least One Episode of Any Hypoglycaemic Event Over 104 Weeks", "description": "Proportion of participants reporting at least one episode of any hypoglycaemic event for saxagliptin added on to metformin versus glipizide added on to metformin over 104 weeks (Safety Analysis Set)", "timeFrame": "Baseline, Week 104"}, {"measure": "Body Weight Change From Baseline to Week 104", "description": "Adjusted mean change from baseline in Body Weight achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 104. Body Weight is a continuous measure, the change from baseline for each participant is calculated as the Week 104 value minus the baseline value.", "timeFrame": "Baseline, Week 104"}, {"measure": "Mean Slope of the Regressions of Change From Week 24 to Week 104 in HbA1c", "description": "Mean slopes of regression of change from Week 24 to Week 104 in HbA1c for saxagliptin added on to metformin versus glipizide added on to metformin (Full Analysis Set) achieved by fitting a mixed model with subject specific slopes for the time effect (weeks on randomized treatment was utilized). This analysis gives an assessment of the durability of the HbA1c effect.", "timeFrame": "Week 24 to Week 104"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes,\n* Treatment with metformin alone on stable doses of 1500 mg or higher per day for at least 8 weeks prior to Visit 1,\n* HbA1c \\>6.5% and \u226410.0%\n\nExclusion Criteria:\n\n* Type 1 diabetes,\n* history of diabetic ketoacidosis or hyperosmolar non-ketonic coma,\n* Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Burkhard Goke", "affiliation": "University of Munich, Germany", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Peter Ohman, MD", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}, {"name": "Deborah Price, MSc", "affiliation": "AstraZeneca", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Research Site", "city": "Hanko", "country": "Finland", "geoPoint": {"lat": 59.83333, "lon": 22.95}}, {"facility": "Research Site", "city": "Helsinki", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"facility": "Research Site", "city": "Kuopio", "country": "Finland", "geoPoint": {"lat": 62.89238, "lon": 27.67703}}, {"facility": "Research Site", "city": "Kuusankoski", "country": "Finland", "geoPoint": {"lat": 60.907, "lon": 26.62437}}, {"facility": "Research Site", "city": "Mikkeli", "country": "Finland", "geoPoint": {"lat": 61.68857, "lon": 27.27227}}, {"facility": "Research Site", "city": "Oulu", "country": "Finland", "geoPoint": {"lat": 65.01236, "lon": 25.46816}}, {"facility": "Research Site", "city": "Tampere", "country": "Finland", "geoPoint": {"lat": 61.49911, "lon": 23.78712}}, {"facility": "Research Site", "city": "Aschaffenburg", "country": "Germany", "geoPoint": {"lat": 49.97704, "lon": 9.15214}}, {"facility": "Research Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Dortmund", "country": "Germany", "geoPoint": {"lat": 51.51494, "lon": 7.466}}, {"facility": "Research Site", "city": "Frankfurt", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "Hamburg", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Research Site", "city": "Hannover", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Research Site", "city": "Mainz", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Research Site", "city": "Mannheim", "country": "Germany", "geoPoint": {"lat": 49.4891, "lon": 8.46694}}, {"facility": "Research Site", "city": "Mulheim", "country": "Germany", "geoPoint": {"lat": 51.43218, "lon": 6.87967}}, {"facility": "Research Site", "city": "Pirna", "country": "Germany", "geoPoint": {"lat": 50.95843, "lon": 13.93702}}, {"facility": "Research Site", "city": "Ratzeburg", "country": "Germany", "geoPoint": {"lat": 53.69961, "lon": 10.77269}}, {"facility": "Research Site", "city": "Reinfeld", "country": "Germany", "geoPoint": {"lat": 53.83184, "lon": 10.49126}}, {"facility": "Research Site", "city": "Rhaunen", "country": "Germany", "geoPoint": {"lat": 49.86322, "lon": 7.34232}}, {"facility": "Research Site", "city": "Schmiedeberg", "country": "Germany", "geoPoint": {"lat": 50.83644, "lon": 13.67622}}, {"facility": "Research Site", "city": "Tubingen", "country": "Germany", "geoPoint": {"lat": 48.52266, "lon": 9.05222}}, {"facility": "Research Site", "city": "Wahlstedt", "country": "Germany", "geoPoint": {"lat": 53.95161, "lon": 10.20626}}, {"facility": "Research Site", "city": "Weinheim", "country": "Germany", "geoPoint": {"lat": 49.54887, "lon": 8.66697}}, {"facility": "Research Site", "city": "Balatonfured", "country": "Hungary", "geoPoint": {"lat": 46.96188, "lon": 17.87187}}, {"facility": "Research Site", "city": "Bekescsaba", "country": "Hungary", "geoPoint": {"lat": 46.68333, "lon": 21.1}}, {"facility": "Research Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Debrecen", "country": "Hungary", "geoPoint": {"lat": 47.53333, "lon": 21.63333}}, {"facility": "Research Site", "city": "Gyula", "country": "Hungary", "geoPoint": {"lat": 46.65, "lon": 21.28333}}, {"facility": "Research Site", "city": "Kalocsa", "country": "Hungary", "geoPoint": {"lat": 46.52639, "lon": 18.98583}}, {"facility": "Research Site", "city": "Kaposvar", "country": "Hungary", "geoPoint": {"lat": 46.36667, "lon": 17.8}}, {"facility": "Research Site", "city": "Kecskemet", "country": "Hungary", "geoPoint": {"lat": 46.90618, "lon": 19.69128}}, {"facility": "Research Site", "city": "Miskolc", "country": "Hungary", "geoPoint": {"lat": 48.1, "lon": 20.78333}}, {"facility": "Research Site", "city": "Mosonmagyarovar", "country": "Hungary", "geoPoint": {"lat": 47.86789, "lon": 17.26994}}, {"facility": "Research Site", "city": "Nyiregyhaza", "country": "Hungary", "geoPoint": {"lat": 47.95539, "lon": 21.71671}}, {"facility": "Research Site", "city": "Szekesfehervar", "country": "Hungary", "geoPoint": {"lat": 47.18995, "lon": 18.41034}}, {"facility": "Research Site", "city": "Bangalore", "state": "Karnataka", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Research Site", "city": "Indore", "state": "Madhya Pradesh", "country": "India", "geoPoint": {"lat": 22.71792, "lon": 75.8333}}, {"facility": "Research Site", "city": "Mumbai", "state": "Mashatra", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "Research Site", "city": "Jaipur", "state": "Rajasthan", "country": "India", "geoPoint": {"lat": 26.91962, "lon": 75.78781}}, {"facility": "Research Site", "city": "Guri", "state": "Gyeonggi-do", "country": "Korea, Republic of", "geoPoint": {"lat": 37.5986, "lon": 127.1394}}, {"facility": "Research Site", "city": "Seongnam", "state": "Gyeonggi-do", "country": "Korea, Republic of", "geoPoint": {"lat": 37.43861, "lon": 127.13778}}, {"facility": "Research Site", "city": "Wonju", "state": "Kangwon-do", "country": "Korea, Republic of", "geoPoint": {"lat": 37.35139, "lon": 127.94528}}, {"facility": "Research Site", "city": "Incheon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "Research Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Uijeongbu-si", "country": "Korea, Republic of", "geoPoint": {"lat": 37.7415, "lon": 127.0474}}, {"facility": "Research Site", "city": "Beek En Donk", "country": "Netherlands", "geoPoint": {"lat": 51.54158, "lon": 5.62603}}, {"facility": "Research Site", "city": "Den Bosch", "country": "Netherlands", "geoPoint": {"lat": 51.27, "lon": 5.59167}}, {"facility": "Research Site", "city": "Den Haag", "country": "Netherlands", "geoPoint": {"lat": 52.07667, "lon": 4.29861}}, {"facility": "Research Site", "city": "Deurne", "country": "Netherlands", "geoPoint": {"lat": 51.46, "lon": 5.79722}}, {"facility": "Research Site", "city": "Dordrecht", "country": "Netherlands", "geoPoint": {"lat": 51.81, "lon": 4.67361}}, {"facility": "Research Site", "city": "Losser", "country": "Netherlands", "geoPoint": {"lat": 52.26083, "lon": 7.00417}}, {"facility": "Research Site", "city": "Nijverdal", "country": "Netherlands", "geoPoint": {"lat": 52.36, "lon": 6.46806}}, {"facility": "Research Site", "city": "Rijswijk", "country": "Netherlands", "geoPoint": {"lat": 52.03634, "lon": 4.32501}}, {"facility": "Research Site", "city": "Roelofarendsveen", "country": "Netherlands", "geoPoint": {"lat": 52.20333, "lon": 4.63333}}, {"facility": "Research Site", "city": "Rotterdam", "country": "Netherlands", "geoPoint": {"lat": 51.9225, "lon": 4.47917}}, {"facility": "Research Site", "city": "Volendam", "country": "Netherlands", "geoPoint": {"lat": 52.495, "lon": 5.07083}}, {"facility": "Research Site", "city": "Bergen", "country": "Norway", "geoPoint": {"lat": 60.39299, "lon": 5.32415}}, {"facility": "Research Site", "city": "Elverum", "country": "Norway", "geoPoint": {"lat": 60.88191, "lon": 11.56231}}, {"facility": "Research Site", "city": "Flatasen", "country": "Norway", "geoPoint": {"lat": 63.38055, "lon": 10.34625}}, {"facility": "Research Site", "city": "Hamar", "country": "Norway", "geoPoint": {"lat": 60.7945, "lon": 11.06798}}, {"facility": "Research Site", "city": "Honefoss", "country": "Norway", "geoPoint": {"lat": 60.16804, "lon": 10.25647}}, {"facility": "Research Site", "city": "Inderoy", "country": "Norway"}, {"facility": "Research Site", "city": "Oslo", "country": "Norway", "geoPoint": {"lat": 59.91273, "lon": 10.74609}}, {"facility": "Research Site", "city": "Radal", "country": "Norway", "geoPoint": {"lat": 60.31063, "lon": 5.34554}}, {"facility": "Research Site", "city": "Skedsmokorset", "country": "Norway", "geoPoint": {"lat": 60.00459, "lon": 11.03278}}, {"facility": "Research Site", "city": "Sogndal", "country": "Norway", "geoPoint": {"lat": 61.22908, "lon": 7.09674}}, {"facility": "Research Site", "city": "Spikkestad", "country": "Norway", "geoPoint": {"lat": 59.74396, "lon": 10.33698}}, {"facility": "Research Site", "city": "Trollasen", "country": "Norway"}, {"facility": "Research Site", "city": "Kazan", "country": "Russian Federation", "geoPoint": {"lat": 55.78874, "lon": 49.12214}}, {"facility": "Research Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Nizhnii Novgorod", "country": "Russian Federation", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "Research Site", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Yaroslavl", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Research Site", "city": "Dolny Kubin", "country": "Slovakia", "geoPoint": {"lat": 49.20983, "lon": 19.30341}}, {"facility": "Research Site", "city": "Kosice - Tahanovce", "country": "Slovakia"}, {"facility": "Research Site", "city": "Moldava Nad Bodvou", "country": "Slovakia", "geoPoint": {"lat": 48.61428, "lon": 20.99957}}, {"facility": "Research Site", "city": "Ruzomberok", "country": "Slovakia", "geoPoint": {"lat": 49.0748, "lon": 19.30751}}, {"facility": "Research Site", "city": "Trnava", "country": "Slovakia", "geoPoint": {"lat": 48.37741, "lon": 17.58723}}, {"facility": "Research Site", "city": "Zilina", "country": "Slovakia", "geoPoint": {"lat": 49.22315, "lon": 18.73941}}, {"facility": "Research Site", "city": "Annan", "state": "Dumfries and Galloway", "country": "United Kingdom", "geoPoint": {"lat": 54.98839, "lon": -3.25647}}, {"facility": "Research Site", "city": "Whitstable", "state": "Kent", "country": "United Kingdom", "geoPoint": {"lat": 51.3607, "lon": 1.0257}}, {"facility": "Research Site", "city": "Hamilton", "state": "Lanarkshire", "country": "United Kingdom", "geoPoint": {"lat": 55.76667, "lon": -4.03333}}, {"facility": "Research Site", "city": "Salford", "state": "Manchester", "country": "United Kingdom", "geoPoint": {"lat": 53.48771, "lon": -2.29042}}, {"facility": "Research Site", "city": "Crawley", "state": "West Sussex", "country": "United Kingdom", "geoPoint": {"lat": 51.11303, "lon": -0.18312}}, {"facility": "Research Site", "city": "Bradford-on-avon", "state": "Wiltshire", "country": "United Kingdom", "geoPoint": {"lat": 51.34772, "lon": -2.25065}}, {"facility": "Research Site", "city": "Blackpool", "country": "United Kingdom", "geoPoint": {"lat": 53.81667, "lon": -3.05}}, {"facility": "Research Site", "city": "Coatbridge", "country": "United Kingdom", "geoPoint": {"lat": 55.86216, "lon": -4.02469}}, {"facility": "Research Site", "city": "Coventry", "country": "United Kingdom", "geoPoint": {"lat": 52.40656, "lon": -1.51217}}, {"facility": "Research Site", "city": "Glasgow", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Research Site", "city": "Motherwell", "country": "United Kingdom", "geoPoint": {"lat": 55.78924, "lon": -3.99187}}, {"facility": "Research Site", "city": "Newcastle", "country": "United Kingdom", "geoPoint": {"lat": 54.97328, "lon": -1.61396}}, {"facility": "Research Site", "city": "Sheffield", "country": "United Kingdom", "geoPoint": {"lat": 53.38297, "lon": -1.4659}}, {"facility": "Research Site", "city": "Ho Chi Minh City", "country": "Vietnam", "geoPoint": {"lat": 10.82302, "lon": 106.62965}}, {"facility": "Research Site", "city": "Ho Chi Minh", "country": "Vietnam", "geoPoint": {"lat": 10.82302, "lon": 106.62965}}]}, "referencesModule": {"references": [{"pmid": "25414932", "type": "DERIVED", "citation": "Cook W, Minervini G, Bryzinski B, Hirshberg B. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgrad Med. 2014 Oct;126(6):19-32. doi: 10.3810/pgm.2014.10.2818."}, {"pmid": "24397584", "type": "DERIVED", "citation": "Mintz ML, Minervini G. Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia. Curr Med Res Opin. 2014 May;30(5):761-70. doi: 10.1185/03007995.2014.880674. Epub 2014 Jan 30."}, {"pmid": "23638466", "type": "DERIVED", "citation": "Goke B, Gallwitz B, Eriksson JG, Hellqvist A, Gause-Nilsson I. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract. 2013 Apr;67(4):307-16. doi: 10.1111/ijcp.12119."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "891 participants were enrolled in the study; 33 participants did not enter the treatment period; 858 participants were randomized and treated.", "groups": [{"id": "FG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg tablets added on to open-label metformin"}, {"id": "FG001", "title": "Glipizide + Metformin", "description": "Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks) added on to open-label metformin"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Randomized and treated", "numSubjects": "428"}, {"groupId": "FG001", "comment": "Randomized and treated", "numSubjects": "430"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Completed 104 weeks of treatment", "numSubjects": "165"}, {"groupId": "FG001", "comment": "Completed 104 weeks of treatment", "numSubjects": "147"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "263"}, {"groupId": "FG001", "numSubjects": "283"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "27"}, {"groupId": "FG001", "numSubjects": "31"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Incorrect enrollment", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Study specific discontinuation criteria", "reasons": [{"groupId": "FG000", "numSubjects": "203"}, {"groupId": "FG001", "numSubjects": "218"}]}, {"type": "Severe non-compliance to protocol", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Safety reasons", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Elevated triglyceride", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Patient moved", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Impossible to determine HbA1c", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg tablets added on to open-label metformin"}, {"id": "BG001", "title": "Glipizide + Metformin", "description": "Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks) added on to open-label metformin"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "428"}, {"groupId": "BG001", "value": "430"}, {"groupId": "BG002", "value": "858"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57.50", "spread": "10.26"}, {"groupId": "BG001", "value": "57.59", "spread": "10.37"}, {"groupId": "BG002", "value": "57.55", "spread": "10.31"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "216"}, {"groupId": "BG001", "value": "198"}, {"groupId": "BG002", "value": "414"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "212"}, {"groupId": "BG001", "value": "232"}, {"groupId": "BG002", "value": "444"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Hemoglobin A1c (HbA1c) Change From Baseline to Week 52", "description": "Adjusted mean change from baseline in HbA1c achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 52 (Per Protocol Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated as the Week 52 value minus the baseline value.", "populationDescription": "Randomized participants who completed the 52 weeks of treatment had both baseline and week 52 HbA1c measurement and had no significant protocol deviations", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent", "timeFrame": "Baseline to 52 Weeks", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg tablets added on to open-label metformin"}, {"id": "OG001", "title": "Glipizide + Metformin", "description": "Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks) added on to open-label metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "293"}, {"groupId": "OG001", "value": "293"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.46", "spread": "0.045"}, {"groupId": "OG001", "value": "7.53", "spread": "0.045"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.74", "spread": "0.042"}, {"groupId": "OG001", "value": "6.71", "spread": "0.042"}]}]}, {"title": "Adjusted Change from Baseline to Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.74", "spread": "0.038"}, {"groupId": "OG001", "value": "-0.80", "spread": "0.038"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "0.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.05", "ciUpperLimit": "0.16", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.053"}]}, {"type": "SECONDARY", "title": "Proportion of Participants Reporting at Least One Episode of Any Hypoglycaemic Event Over 52 Weeks", "description": "Proportion of participants reporting at least one episode of any hypoglycaemic event for saxagliptin added on to metformin versus glipizide added on to metformin over 52 weeks (Safety Analysis Set)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "From Baseline to Week 52", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg tablets added on to open-label metformin"}, {"id": "OG001", "title": "Glipizide + Metformin", "description": "Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks) added on to open-label metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "428"}, {"groupId": "OG001", "value": "430"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3", "lowerLimit": "-38.1", "upperLimit": "-28.5"}, {"groupId": "OG001", "value": "36.3", "lowerLimit": "0", "upperLimit": "0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Between group comparison significant after controlling overall alpha of the study", "statisticalMethod": "Fisher Exact", "paramType": "Mean Difference (Net)", "paramValue": "-33.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-38.1", "ciUpperLimit": "-28.5"}]}, {"type": "SECONDARY", "title": "Body Weight Change From Baseline to Week 52", "description": "Adjusted mean change from baseline in Body Weight achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 52 (Safety Analysis Set). Body Weight is a continuous measure, the change from baseline for each participant is calculated as the Week 52 (LOCF) value minus the baseline value.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in the LOCF analysis, participants must have had a baseline and at least 1 post-baseline measurement", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kilogram", "timeFrame": "Baseline, Week 52 (Last Observation Carried Forward)", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg tablets added on to open-label metformin"}, {"id": "OG001", "title": "Glipizide + Metformin", "description": "Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks) added on to open-label metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "424"}, {"groupId": "OG001", "value": "426"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "88.7", "spread": "0.91"}, {"groupId": "OG001", "value": "88.6", "spread": "0.95"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "87.6", "spread": "0.90"}, {"groupId": "OG001", "value": "89.7", "spread": "0.99"}]}]}, {"title": "Adjusted Change from Baseline to Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "0.17"}, {"groupId": "OG001", "value": "1.1", "spread": "0.17"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Between group comparison significant after controlling overall alpha of the study", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-2.2", "ciPctValue": "95", "ciLowerLimit": "-2.7", "ciUpperLimit": "-1.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.24"}]}, {"type": "SECONDARY", "title": "Mean Slope of the Regressions of Change From Week 24 to Week 52 in HbA1c", "description": "Mean slopes of regression of change from Week 24 to Week 52 in HbA1c for saxagliptin added on to metformin versus glipizide added on to metformin (Per Protocol Analysis Set) achieved by fitting a mixed model with subject specific slopes for the time effect (weeks on randomized treatment was utilized). This analysis gives an assessment of the durability of the HbA1c effect.", "populationDescription": "Randomized participants who completed the 52 weeks of treatment had both baseline and week 52 HbA1c measurement and had no significant protocol deviations", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent", "timeFrame": "Week 24 to Week 52", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg tablets added on to open-label metformin"}, {"id": "OG001", "title": "Glipizide + Metformin", "description": "Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks) added on to open-label metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "289"}, {"groupId": "OG001", "value": "293"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.001", "spread": "0.001"}, {"groupId": "OG001", "value": "0.004", "spread": "0.001"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.040", "pValueComment": "Between group comparison significant after controlling overall alpha of the study", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "-0.002", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.0046", "ciUpperLimit": "-0.0001", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.001"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Hemoglobin A1c (HbA1c) Change From Baseline to Week 104", "description": "Adjusted mean change from baseline in HbA1c achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 104 (Full Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated as the Week 104 value minus the baseline value.", "populationDescription": "Number of subjects with observed values at Week 104 was n=184 for saxagliptin + metformin and n=160 for glipizide + metformin", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent", "timeFrame": "Baseline, Week 104", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg tablets added on to open-label metformin"}, {"id": "OG001", "title": "Glipizide + Metformin", "description": "Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks) added on to open-label metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "423"}, {"groupId": "OG001", "value": "423"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.65", "spread": "0.044"}, {"groupId": "OG001", "value": "7.65", "spread": "0.041"}]}]}, {"title": "Week 104", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.27", "spread": "0.050"}, {"groupId": "OG001", "value": "7.27", "spread": "0.046"}]}]}, {"title": "Adjusted Change from Baseline to Week 104", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.41", "spread": "0.041"}, {"groupId": "OG001", "value": "-0.35", "spread": "0.043"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Repeated Measures", "paramType": "Mean Difference (Net)", "paramValue": "-0.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.17", "ciUpperLimit": "0.06", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.059"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Proportion of Participants Reporting at Least One Episode of Any Hypoglycaemic Event Over 104 Weeks", "description": "Proportion of participants reporting at least one episode of any hypoglycaemic event for saxagliptin added on to metformin versus glipizide added on to metformin over 104 weeks (Safety Analysis Set)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Baseline, Week 104", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg tablets added on to open-label metformin"}, {"id": "OG001", "title": "Glipizide + Metformin", "description": "Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks) added on to open-label metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "428"}, {"groupId": "OG001", "value": "430"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.5"}, {"groupId": "OG001", "value": "38.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-34.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-39.8", "ciUpperLimit": "-30.0"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Body Weight Change From Baseline to Week 104", "description": "Adjusted mean change from baseline in Body Weight achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 104. Body Weight is a continuous measure, the change from baseline for each participant is calculated as the Week 104 value minus the baseline value.", "populationDescription": "Number of subjects with observed values at Week 104 was n=186 for saxagliptin + metformin and n=165 for glipizide + metformin", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kilograms", "timeFrame": "Baseline, Week 104", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg tablets added on to open-label metformin"}, {"id": "OG001", "title": "Glipizide + Metformin", "description": "Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks) added on to open-label metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "424"}, {"groupId": "OG001", "value": "426"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "88.69", "spread": "0.905"}, {"groupId": "OG001", "value": "88.57", "spread": "0.955"}]}]}, {"title": "Week 104", "categories": [{"measurements": [{"groupId": "OG000", "value": "87.47", "spread": "0.898"}, {"groupId": "OG001", "value": "89.80", "spread": "0.987"}]}]}, {"title": "Adjusted Change from Baseline to Week 104", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.47", "spread": "0.200"}, {"groupId": "OG001", "value": "1.29", "spread": "0.205"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Repeated Measures", "paramType": "Mean Difference (Net)", "paramValue": "-2.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.32", "ciUpperLimit": "-2.20", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.286"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Mean Slope of the Regressions of Change From Week 24 to Week 104 in HbA1c", "description": "Mean slopes of regression of change from Week 24 to Week 104 in HbA1c for saxagliptin added on to metformin versus glipizide added on to metformin (Full Analysis Set) achieved by fitting a mixed model with subject specific slopes for the time effect (weeks on randomized treatment was utilized). This analysis gives an assessment of the durability of the HbA1c effect.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent", "timeFrame": "Week 24 to Week 104", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg tablets added on to open-label metformin"}, {"id": "OG001", "title": "Glipizide + Metformin", "description": "Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks) added on to open-label metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "373"}, {"groupId": "OG001", "value": "377"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0041", "spread": "0.0005"}, {"groupId": "OG001", "value": "0.0076", "spread": "0.0005"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "-0.0035", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.0048", "ciUpperLimit": "-0.0022", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0007"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg tablets added on to open-label metformin", "seriousNumAffected": 54, "seriousNumAtRisk": 428, "otherNumAffected": 105, "otherNumAtRisk": 428}, {"id": "EG001", "title": "Glipizide + Metformin", "description": "Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks) added on to open-label metformin", "seriousNumAffected": 55, "seriousNumAtRisk": 430, "otherNumAffected": 201, "otherNumAtRisk": 430}], "seriousEvents": [{"term": "Atrial Fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 430}]}, {"term": "Coronary Artery Disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Angina Pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Atrioventricular Block Complete", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Cardiac Failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Coronary Artery Stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Myocardial Ischemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Supraventricular Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Ventricular Fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Angina Unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 430}]}, {"term": "Arteriosclerosis Coronary Artery", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Coronary Artery Occlusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Arthropathy", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Intervertebral Disc Protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Jaw Cyst", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Anal Abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Pulmonary Tuberculosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Helicobacter Gastritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Superinfection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Femoral Neck Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Head Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Meniscus Lesion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Concussion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Femur Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Ligament Rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Open Wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Tendon Rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Bladder Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Colon Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Metastasis To Liver", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Salivary Gland Neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Inguinal Hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Acute Abdomen", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Gastroesophageal Reflux Disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 430}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Pancreatitis Acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Allergy To Arthropod Sting", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Bronchitis Chronic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Dyspnea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Laryngeal Edema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Pulmonary Embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Hydrocele", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Deafness Bilateral", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Biliary Colic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Hepatitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Cerebrovascular Disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Cerebral Ischemia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Cerebrovascular Accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Ischemic Stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Renal Failure Acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Urinary Retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Endometrial Hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Aortic Aneurysm", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 430}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Diabetes Mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Herpes Zoster Ophthalmic", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Salmonella Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Biliary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 420}]}, {"term": "Acute Myeloid Leukemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Metastases to Central Nervous System", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Thyroid Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Bladder Neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Bronchial Carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Colon Neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Lip Neoplasm Malignant Stage Unspecified", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Lung Neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Malignant Melanoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Renal Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Tumor Ulceration", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Breast Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Osteochondrosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Lumbar Vertebral Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Patella Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Upper Limb Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Humerus Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Hypertensive Encephalopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Vertebrobasilar Insufficiency", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Transient Ischemic Attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Abdominal Pain Upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Food Poisoning", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Gastric Ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Rectal Hemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Upper Gastrointestinal Hemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Gastric Hemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Retinal Vein Occlusion", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Device Malfunction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 430}]}, {"term": "Benign Prostatic Hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Arteriosclerosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Hypertensive Crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 430}]}, {"term": "Hyperthyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Agitation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Circulatory Collapse", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 430}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 25, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 430}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 46, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 41, "numAtRisk": 430}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 165, "numAtRisk": 430}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 25, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 430}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 428}, {"groupId": "EG001", "numAffected": 27, "numAtRisk": 430}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M9023", "name": "Glipizide", "relevance": "LOW"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}